Table 1 | Previous studies reported on use of RNAi technology..

No.	RNAi strategy used	System tested	Target region	Reference
1	Plasmid-encoded dual siRNAs	In vitro	3D	57
2	19-mer siRNAs	In vitro	2A	58
3	19-mer siRNAs	In vitro and in vivo	2A	59
4	19-mer siRNAs	In vitro	3D	60
5	19-mer siRNAs	In vitro	3D	61
6	Plasmid-encoded shRNAs	In vitro and in vivo	3D and VP1	62
7	Plasmid-encoded shRNAs	In vitro	CAR gene coding for CVB3 receptor	63
8	Viral-vector encoded shRNAs	In vivo	2C	64
9	Viral-vector encoded shRNAs	In vitro and in vivo	3D	65
10	19-mer siRNAs and siRNAs containing locked nucleic acids (LNAs)	In vitro	3D and 5′UTR	66
11	siRNAs containing locked nucleic acids (LNAs)	In vitro	5′UTR	67
12	Multiple 19-mer siRNAs	In vitro	3D	68
13	19-mer siRNAs and plasmid-encoded siRNAs	In vitro	3D and CAR gene coding for CVB3 receptor	69

Table 1: Previous studies reported on use of RNAi technology on Coxsackievirus B3 (CB3).

Goto home»